Nelotanserin

Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia.[1] It was shown to be effective and well tolerated in clinical trials,[2][3] but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.[4] Research continues on newer analogues which may potentially be more successful.[5] More recently, nelotanserin has been repurposed for the treatment of Lewy body disease.[6] As of 2017, it is in phase II clinical trials for this indication.[6]

Nelotanserin
Clinical data
Other namesAPD-125
Routes of
administration
Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H15BrF2N4O2
Molar mass437.245 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

References

  1. Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, et al. (March 2010). "Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (5): 1923–36. doi:10.1021/jm9007328. PMID 20143782.
  2. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. (December 2008). "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep. 31 (12): 1663–71. doi:10.1093/sleep/31.12.1663. PMC 2603489. PMID 19090322.
  3. Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, et al. (January 2010). "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia". The Journal of Pharmacology and Experimental Therapeutics. 332 (1): 281–90. doi:10.1124/jpet.109.160994. PMID 19841476. S2CID 2759858.
  4. "APD125 for Insomnia". Arena Pharmaceuticals, Inc. Archived from the original on 2009-08-26.
  5. Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, et al. (August 2010). "Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (15): 5696–706. doi:10.1021/jm100479q. PMID 20684606.
  6. "Nelotanserin - Axovant Gene Therapies". Adis International Ltd. Springer Science+Business Media.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.